Analytics story: Count of Patients or count of TRx? - 06/24

When analyzing Healthcare Professionals (HCP) level market data from open claims data sources, the question arises: should we use the count of Patients (Patients) or the count of TRx (TRx) as the key metric?

Generally, TRx is the preferred metric because it can be converted into monetary value ($), considering the number of refills in the TRx. TRx provides granular data and accurately quantifies the HCP potential.

However, Patients may be more relevant in cases of orphan drugs or when checking the line of therapies (LOT), such as in the context of Oncology drugs like Opdivo.

For example, consider two HCPs in prescribing regular patented drugs: HCP A has 10 Patients with 200 TRx in the recent 12 months, while HCP B has 50 Patients with 100 TRx. HCP A is considered high potential because it has 2x more TRx than HCP B.

But in case of orphan drug or Oncology, HCP C has 10 patients with 120 TRx and HCP D has 20 patients with 240 TRx (since compliance is very high in case of such drugs and there is very less switching between drugs), count of patients can also be considered

Follow me on LinkedIn